Protein-protein interactions as antibiotic targets: A medicinal chemistry perspective.
antibacterial
antibiotic
protein-protein interaction (PPI)
Journal
Medicinal research reviews
ISSN: 1098-1128
Titre abrégé: Med Res Rev
Pays: United States
ID NLM: 8103150
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
18
10
2017
revised:
28
05
2018
accepted:
03
06
2018
pubmed:
14
7
2018
medline:
9
7
2021
entrez:
14
7
2018
Statut:
ppublish
Résumé
There are 27 small molecule protein-protein interaction (PPI) modulators in Phase I, II, and III clinical trials targeting cancer, viruses, autoimmune disorders, and as immune suppression agents. Targeting PPIs as an antibiotic drug discovery strategy remains in relative infancy by comparison. However, a number of molecules are in development which target PPI within the replisome, divisome, transcriptome, and translatome are showing significant promise at the medicinal chemistry stage of drug development. Hence, the success of future PPI agents as antibiotics will build upon the techniques and design strategies of these molecules.
Substances chimiques
Anti-Bacterial Agents
0
Small Molecule Libraries
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
469-494Informations de copyright
© 2018 Wiley Periodicals, Inc.
Références
Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161-168.
Shore CK, Coukell A. Roadmap for antibiotic discovery. Nat Microbiol. 2016;1:16083.
Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
Wright GD. Molecular mechanisms of antibiotic resistance. Chem Commun. 2011;47:4055.
Mullard A. Preclinical antibiotic pipeline gets a pick-me-up. Nat Rev Drug Discov. 2017;16:741-742.
de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050. PLoS Med. 2016;13:1-6.
Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24:71-109.
Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline at the end of 2015. J Antibiot. 2017;70:3-24.
Butler MS, Cooper MA. Antibiotics in the clinical pipeline in 2011. J Antibiot. 2011;64:413-425.
Rosamond J. Harnessing the power of the genome in the search for new antibiotics. Science. 2000;287:1973-1976.
CarB-X http://www.carb-x.org.
Arkin MR, Tang Y, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol. 2014;21:1102-1114.
Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Oncogenic protein interfaces: small molecules, big challenges. Nat Rev Cancer. 2014;14:248-262.
Sperandio O, Reynès CH, Camproux A, Villoutreix BO. Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov Today. 2010;15:220-229.
Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004;3:301-317.
Dalrymple BP, Kongsuwan K, Wijffels G, Dixon NE, Jennings PA. A universal protein-protein interaction motif in the eubacterial DNA replication and repair systems. Proc Natl Acad Sci. 2001;98:11627-11632.
Shakhnovich EA, Hung DT, Pierson E, Lee K, Mekalanos JJ. Virstatin inhibits dimerization of the transcriptional activator ToxT. Proc Natl Acad Sci USA. 2007;104:2372-2377.
Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science. 1995;267:383-386.
Chen J, Sawyer N, Regan L. Protein-protein interactions: general trends in the relationship between binding affinity and interfacial buried surface area. Protein Sci. 2013;22:510-515.
Milroy LG, Grossmann TN, Hennig S, Brunsveld L, Ottmann C. Modulators of protein-protein interactions. Chem Rev. 2014;114:4695-4748.
Petta I, Lievens S, Libert C, Tavernier J, De Bosscher K. Modulation of protein-protein interactions for the development of novel therapeutics. Mol Ther. 2015;2:1-12.
Sijbesma E, Skora L, Leysen S, et al. Identification of two secondary ligand binding sites in 14-3-3 proteins using fragment screening. Biochemistry. 2017;56:3972-3982.
Rognan D. Rational design of protein-protein interaction inhibitors. Med Chem Commun. 2014;6:51-60.
Spitzer GM, Heiss M, Mangold M, et al. One concept three implementations of 3D pharmacophore-based virtual screening: distinct coverage of chemical search space. J Chem Inf Model. 2010;50:1241-1247.
Chen L, Morrow JK, Tran HT, Phatak SS, Du-Cuny L, Zhang S. From laptop to benchtop to bedside: structure-based drug design on protein targets. Curr Pharm Des. 2012;18:1217-1239.
Mayr LM, Fuerst P. The future of high-throughput screening. J Biomol Screen. 2008;13:443-448.
Szymański P, Markowicz M, Mikiciuk-Olasik E. Adaptation of high-throughput screening in drug discovery-toxicological screening tests. Int J Mol Sci. 2011;13:427-452.
Clark RL, Johnston BF, Mackay SP, Breslin CJ, Robertson MN, Harvey AL. The drug discovery portal: a resource to enhance drug discovery from academia. Drug Discov Today. 2010;15:15-16.
Von Kleist L, Stahlschmidt W, Bulut H, et al. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell. 2011;146:471-484.
Hann MM, Oprea TI. Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol. 2004;8:255-263.
Fernandes TG, Diogo MM, Clark DS, Dordick JS, Cabral JMS. High-throughput cellular microarray platforms: applications in drug discovery toxicology and stem cell research. Trends Biotechnol. 2009;27:342-349.
Martis E. High-throughput screening: the hits and leads of drug discovery-an overview. J Appl Pharm Sci. 2011;1:2-10.
Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53:2719-2740.
Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H. Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov. 2016;15:605-619.
Nobrega FL, Cabrita EJ. Saturation-transfer difference (STD) NMR : a simple and fast method for ligand screening and characterization of protein binding. J Chem Educ. 2011;88:990-994.
Harner MJ, Frank AO, Fesik SW. Fragment-based drug discovery using NMR spectroscopy. J Biomol NMR. 2013;56:65-75.
Neumann T, Junker H-D, Schmidt K, Sekul R. SPR-based fragment screening: advantages and applications. Curr Top Med Chem. 2007;7:1630-1642.
Hallenbeck KK, Davies JL, Merron C, et al. A liquid chromatography-mass spectrometry method for screening disulfide tethering fragments. SLAS Discov. 2018;23:183-192.
Silvestre HL, Blundell TL, Abell C, Ciulli A. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc Natl Acad Sci. 2013;110:12984-12989.
Öster L, Tapani S, Xue Y, Käck H. Successful generation of structural information for fragment-based drug discovery. Drug Discov Today. 2015;20:1104-1111.
Joseph-McCarthy D, Campbell AJ, Kern G, Moustakas D. Fragment-based lead discovery and design. J Chem Inf Model. 2014;54:693-704.
Jhoti H, Cleasby A, Verdonk M, Williams G. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol. 2007;11:485-493.
Sanders MPA, McGuire R, Roumen L, et al. From the protein's perspective: the benefits and challenges of protein structure-based pharmacophore modeling. Med Chem Commun. 2012;3:28-38.
Wermuth CG, Ganellin CR, Lindberg P, Mitscher LA. Glossary of terms used. Pure Appl Chem. 1998;70:1129-1143.
Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today. 2010;15:444-450.
Anderson AC. The process of structure-based drug design. Chem Biol. 2003;10:787-797.
Smith GR, Sternberg MJE. Prediction of protein-protein interactions by docking methods. Curr Opin Struct Biol. 2002;12:28-35.
Robinson A, Brzoska AJ, Turner KM, et al. Essential biological processes of an emerging pathogen: dNA replication transcription and cell division in Acinetobacter Spp. Microbiol Mol Biol Rev. 2010;74:273-297.
Wijffels G, Johnson WM, Oakley AJ, et al. Binding inhibitors of the bacterial sliding clamp by design. J Med Chem. 2011;54:4831-4838.
Robinson A, Causer RJ, Dixon NE. Architecture and conservation of the bacterial DNA replication machinery an underexploited drug target. Curr Drug Targets. 2012;13:352-372.
Hale CA, De Boer PAJ. Direct binding of FtsZ to ZipA an essential component of the septal ring structure that mediates cell division in E coli. Cell. 1997;88:175-185.
Jennings LD, Foreman KW, Rush TS, et al. Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction. Bioorganic Med Chem. 2004;12:5115-5131.
Erickson HP, Anderson DE, Osawa M. FtsZ in bacterial cytokinesis: cytoskeleton and force generator all in one. Microbiol Mol Biol Rev. 2010;74:504-528.
Hale CA, De Boer PAJ. Recruitment of ZipA to the septal ring of Escherichia coli is dependent on FtsZ and independent of FtsA. J Bacteriol. 1999;181:167-176.
Kenny CH, Ding W, Kelleher K, et al. Development of a fluorescence polarization assay to screen for inhibitors of the FtsZ/ZipA interaction. Anal Biochem. 2003;323:224-233.
Rush TS, Grant JA, Mosyak L, Nicholls A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J Med Chem. 2005;48:1489-1495.
Mosyak L, Zhang Y, Glasfeld E, et al. The bacterial cell-division protein ZipA and its interaction with an FtsZ fragment revealed by X-ray crystallography. EMBO J. 2000;19:3179-3191.
Tsao DHH, Sutherland AG, Jennings LD, et al. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. Bioorg Med Chem. 2006;14:7953-7961.
Sutherland AG, Alvarez J, Ding W, et al. Structure-based design of carboxybiphenylindole inhibitors of the ZipA-FtsZ interaction. Org Biomol Chem. 2003;1:4138-4140.
Jennings LD, Foreman KW, Rush TS, et al. Design and synthesis of indolo[23-A]quinolizin-7-one inhibitors of the ZipA-FtsZ interaction. Bioorganic Med Chem Lett. 2004;14:1427-1431.
Georgescu RE, Yurieva O, Kim SS, Kuriyan J, Kong XP, O'Donnell M. Structure of a small-molecule inhibitor of a DNA polymerase sliding clamp. Proc Natl Acad Sci USA. 2008;105:11116-11121.
Yin Z, Wang Y, Whittell LR, et al. DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem Biol. 2014;21:481-487.
Yin Z, Whittell LR, Wang Y, et al. Bacterial sliding clamp inhibitors that mimic the sequential binding mechanism of endogenous linear motifs. J Med Chem. 2015;58:4693-4702.
Wijffels G, Dalrymple BP, Prosselkov P, et al. Inhibition of protein interactions with the β2 sliding clamp of Escherichia coli DNA polymerase III by peptides from β2-binding proteins. Biochemistry. 2004;43:5661-5671.
Yin Z, Whittell LR, Wang Y, et al. Discovery of lead compounds targeting the bacterial sliding clamp using a fragment-based approach. J Med Chem. 2014;57:2799-2806.
Robertson MJ, Horatscheck A, Sauer S, et al. 5-Aryl-2-(naphtha-1-Yl)sulfonamido-thiazol-4(5H)-ones as clathrin inhibitors. Org Biomol Chem. 2016;14:11266-11278.
Meanwell NA. Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem. 2011;54:2529-2591.
Lu D, Windsor MA, Gellman SH, Keck JL. Peptide inhibitors identify roles for SSB C-terminal residues in SSB/exonuclease I complex formation. Biochemistry. 2009;48:6764-6771.
Lohman TM, Ferrari ME. Escherichia coli Single-stranded DNA-binding protein: multiple DNA-binding modes and cooperativities. Annu Rev Biochem. 1994;63:527-570.
Lu D, Keck JL. Structural basis of Escherichia coli single-stranded DNA-binding protein stimulation of exonuclease I. Proc Natl Acad Sci. 2008;105:9169-9174.
Lu D, Bernstein DA, Satyshur KA, Keck JL. Small-molecule tools for dissecting the roles of SSB/protein interactions in genome maintenance. Proc Natl Acad Sci USA. 2010;107:633-638.
Marceau AH, Bernstein DA, Walsh BW, Shapiro W, Simmons LA, Keck JL. Protein interactions in genome maintenance as novel antibacterial targets. PLoS One. 2013;8:e58765.
Ma C, Yang X, Lewis PJ. Bacterial transcription as a target for antibacterial drug development. Microbiol Mol Biol Rev. 2016;80:139-160.
Molodtsov V, Nawarathne IN, Scharf NT, et al. X-ray crystal structures of the Escherichia coli RNA polymerase in complex with benzoxazinorifamycins. J Med Chem. 2013;56:4758-4763.
Borukhov S, Nudler E. RNA polymerase: the vehicle of transcription. Trends Microbiol. 2008;16:126-134.
Lewis PJ, Doherty GP, Clarke J. Transcription factor dynamics. Microbiology. 2008;154:1837-1844.
Lüttgen H, Robelek R, Mühlberger R, et al. Transcriptional regulation by antitermination Interaction of RNA with NusB protein and NusB/NusE protein complex of Escherichia coli. J Mol Biol. 2002;316:875-885.
Ingham CJ, Dennis J, Furneaux PA. Autogenous regulation of transcription termination factor rho and the requirement for Nus factors in Bacillus subtilis. Mol Microbiol. 1999;31:651-663.
Yang X, Ma C, Lewis PJ. Identification of inhibitors of bacterial RNA polymerase. Methods. 2015;86:45-50.
Andre E, Bastide L, Michaux-Charchon S, et al. Novel synthetic molecules targeting the bacterial RNA polymerase assembly. J Antimicrob Chemother. 2006;57:245-251.
Ma C, Yang X, Kandemir H, et al. Inhibitors of bacterial transcription initiation complex formation. ACS Chem Biol. 2013;8:1972-1980.
Villain-Guillot P, Gualtieri M, Bastide L, et al. Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms. J Med Chem. 2007;50:4195-4204.
Arhin F, Bélanger O, Ciblat S, et al. A new class of small molecule RNA polymerase inhibitors with activity against rifampicin-resistant Staphylococcus aureus. Bioorganic Med Chem. 2006;14:5812-5832.
Artsimovitch I, Chu C, Lynch AS, Landick R. A new class of bacterial RNA polymerase inhibitor affects nucleotide addition. Science. 2003;302:650-654.
Larsen SD, Hester MR, Craig Ruble J, et al. Discovery and initial development of a novel class of antibacterials: inhibitors of Staphylococcus aureus transcription/translation. Bioorganic Med Chem Lett. 2006;16:6173-6177.
Hinsberger S, Hüsecken K, Groh M, Negri M, Haupenthal J, Hartmann RW. Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization. J Med Chem. 2013;56:8332-8338.
Ma C, Yang X, Lewis PJ. Bacterial transcription inhibitor of RNA polymerase holoenzyme formation by structure-based drug design: from in silico screening to validation. ACS Infect Dis. 2016;2:39-46.
Mielczarek M, Devakaram RV, Ma C, et al. Synthesis and biological activity of novel bis-indole inhibitors of bacterial transcription initiation complex formation. Org Biomol Chem. 2014;12:2882-2894.
Burmann M, Rösch P. The role of E coli nus-factors in transcription regulation and transcription: translation coupling. Transcription. 2011;2:130-134.
Santangelo TJ, Artsimovitch I. Termination and antitermination: rNA polymerase runs a stop sign. Nat Rev Microbiol. 2011;9:319-329.
Das R, Loss S, Li J, et al. Structural biophysics of the NusB : nusE antitermination complex. J Mol Biol. 2008;376:705-720.
Stagno JR, Altieri AS, Bubunenko M, et al. Structural basis for RNA recognition by NusB and NusE in the initiation of transcription antitermination. Nucleic Acids Res. 2011;39:7803-7815.
Luo X, Hsiao H, Bubunenko M, et al. Structural and functional analysis of the E coli NusB-S10 transcription antitermination complex. Mol Cell. 2008;32:791-802.
Cossar PJ, Ma C, Gordon CP, Ambrus JI, Lewis PJ, McCluskey A. Identification and validation of small molecule modulators of the NusB-NusE interaction. Bioorg Med Chem Lett. 2017;27:162-167.
Cossar PJ, Abdel-Hamid MK, Ma C, et al. Small-molecule inhibitors of the NusB-NusE protein-protein interaction with antibiotic activity. ACS Omega. 2017;2:3839-3857.
Yang X, Luo MJ, Yeung ACM, et al. First-in-class inhibitor of ribosomal RNA synthesis with antimicrobial activity against Staphylococcus aureus. Biochemistry. 2017;56:5049-5052.
Hung DT, Shakhnovich EA, Pierson E, Mekalanos JJ. Small-molecule inhibitor of vibrio cholerae virulence and intestinal colonization. Science. 2005;310:670-674.
Champion GA, Neely MN, Brennan MA, DiRita VJ. A branch in the ToxR regulatory cascade of vibrio cholerae revealed by characterization of ToxT mutant strains. Mol Microbiol. 1997;23:323-331.
Lin Y, Li Y, Zhu N, et al. The antituberculosis antibiotic capreomycin inhibits protein synthesis by disrupting interaction between ribosomal proteins L12 and L10. Antimicrob Agents Chemother. 2014;58:2038-2044.
Lin Y, Li YY, Zhu Y, et al. Identification of antituberculosis agents that target ribosomal protein interactions using a yeast two-hybrid system. Proc Natl Acad Sci USA. 2012;109:17412-17417.
Oleinikov A, Perroud B, Wang B, Traut R. Structural and functional domains of Escherichia coli ribosomal protein L7/L12 The hinge region is required for activity. J Biol Chem. 1993;268:917-922.
Hagiya A, Naganuma T, Maki Y, et al. A mode of assembly of P0 P1 and P2 proteins at the GTPase-associated center in animal ribosome: in vitro analyses with P0 truncation mutants. J Biol Chem. 2005;280:39193-39199.
Bozic I, Reiter JG, Allen B, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife. 2013;2013:1-15.
Brem J, Van Berkel SS AikW, et al. Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β 2-lactamase inhibition. Nat Chem. 2014;6:1084-1090.